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Sulfites are frequently used food and drug additives.
Ingestion of sulfite residues has been documented to trigger asthmatic reactions in
sensitive individuals.
Sulfite-induced asthma occurs in less than 5% of asthmatic individuals, and those with
severe, persistent asthma are at greatest risk.
The diagnosis of sulfite-induced asthma is best made by blinded oral challenge with
assessment of lung function.
Labeling regulations in the United States alert sulfite-sensitive individuals to the presence of sulfites in foods, which must then be avoided.

Introduction
Sulfites or sulfiting agents include sulfur dioxide (SO2), sulfurous acid (H2SO3), and any of
several inorganic sulfite salts that may liberate SO2 under their conditions of use. The inorganic sulfite salts include sodium and potassium metabisulfite (Na2S2O5, K2S2O5), sodium
and potassium bisulfite (NaHSO3, KHSO3), and sodium and potassium sulfite (Na2SO3,
K2SO3). Sulfites have a long history of use as food ingredients, although potassium sulfite
and sulfurous acid are not permitted for use in foods in the United States [1]. Sulfites occur
naturally in many foods, especially fermented foods such as wines [1]. In addition, sulfites
have long been used as ingredients in pharmaceuticals [2, 3].
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Over the past 30 years, questions have arisen about the safety of the continued use of
sulfites in foods and drugs. These concerns were first voiced following the independent
observations in 1981 by David Allen in Australia and Donald Stevenson and Ronald Simon
in the United States of the role of sulfites in triggering asthmatic reactions in some sensitive
individuals [4–6]. It is now apparent that sulfite sensitivity affects only a small subgroup
of the asthmatic population [6–8]. But, concerns remain because sulfite-induced asthma
can be severe—even life-threatening—in some sensitive individuals. Accordingly, the use
of sulfites in foods and drugs has changed considerably over the years. Sulfites have been
replaced in some products, levels have been reduced in others, and the search for effective
alternatives continues. Federal regulations have restricted the use of sulfites in certain food
products in the United States.
Clinical manifestations of sulfite sensitivity
A host of adverse reactions have been attributed to sulfiting agents, including asthma, anaphylaxis, urticaria, diarrhea, abdominal pain and cramping, nausea and vomiting, pruritis, localized angioedema, difficulty in swallowing, faintness, headache, chest pain, loss of
consciousness, “change in body temperature,” “change in heart rate,” and nonspecific
rashes. With the notable exception of the role of sulfites in asthma, the causative role for
sulfites in these conditions has not been fully confirmed. For normal individuals, exposure
to sulfiting agents appears to pose little risk. Toxicity studies in normal volunteers showed
that ingestion of 400 mg of sulfite daily for 25 days had no adverse effect [9].
Nonasthmatic responses on oral exposure to sulfites
Various authors have suggested adverse reactions involving several organ systems following oral exposure to sulfites, but for the most part these effects have not been substantiated
by double-blind, placebo-controlled (DBPC) provocation studies. In a preliminary report,
Flaherty et al. [10] presented a patient who appeared to have hepatotoxicity as manifested
by changes in liver function tests following challenge with potassium metabisulfite. Meggs
et al. [11] failed to demonstrate any role for sulfites among eight individuals with systemic
mastocytosis. Schwartz [12] described two nonasthmatic subjects who developed abdominal
distress and hypotension associated with oral challenge with potassium metabisulfite. Placebocontrolled challenges proved negative, however.
Sulfites have also been implicated as possible causative factors in persistent rhinitis [13].
The role of sulfites was evaluated in a group of 226 patients with persistent rhinitis using
DBPC challenges after 1 month on an additive-free diet. Challenges with up to 20 mg of
sodium metabisulfite elicited both objective (sneezing, rhinorrhea) and subject (nasal
blockage and itching) symptoms in six of 20 individuals who reported improvement in
rhinitis on the additive-free diet [13]. A reduction of ≥ 20% in nasal peak inspiratory flow
rate was also observed in these six subjects [13].
Cutaneous adverse reactions suggestive of hypersensitivity responses have been observed but confirmed by challenge in only a few isolated individual cases. Epstein [14]
described a patient who developed contact sensitivity, as confirmed by appropriate patch
testing, through exposure to sulfiting agents used in a restaurant. Subsequently, several

2

TAYLOR, BUSH, AND NORDLEE, FOOD ALLERGY (2014)

other cases of occupational contact sensitivity of sulfites have been described [15, 16]. The
ingestion of sulfites has been reported to elicit urticaria in a very few cases as confirmed
by DBPC challenges [17], single-blind challenges [18, 19], or open challenges [20]; in other
cases, urticarial responses were not confirmed by oral challenge [21]. Angioedema attributable to the ingestion of sulfiting agents was reported in two of these patients, but only
urticaria was confirmed by open challenge with potassium metabisulfite [20]. Wuthrich
[18] conducted single-blind, placebo-controlled challenges with sodium bisulfite in 245 patients with suspected sulfite sensitivity. Fifty-seven (15%) of the challenges were positive,
including 17 patients with urticaria/angioedema, seven patients with rhinitis, and five patients with local anesthetic reactions. Wuthrich et al. [19] reported a case of acute intermittent urticaria with an associated vasculitis due to sulfites based on a placebo-controlled,
single-blind challenge. Huang and Fraser [22] presented an individual who developed palmar and plantar pruritis, generalized urticaria, laryngeal edema, and severe abdominal
pain with fulminant diarrhea after ingesting sulfiting agents. In a controlled challenge with
a local anesthetic containing 0.9 μg of sodium metabisulfite, the patient experienced palmar pruritis but no generalized urticaria. Yao and Bloomberg [23] identified a single patient with urticaria occurring a few hours after oral challenge with a cumulative dose of
390 mg of sodium metabisulfite. Sulfites have also been occasionally implicated in exacerbation of chronic urticaria with the largest trial involving 36 subjects [24]. However, studies
of chronic urticaria are often complicated by the underlying condition and breakthrough
urticaria occurring if medications are withheld during challenges. The toxicological mechanism involved in these cutaneous reactions has not been elucidated.
Anaphylaxis-like events have been described in several individuals, although appropriate confirmatory testing was performed only in some instances. Prenner and Stevens
[25] described a nonasthmatic individual who developed urticaria, pruritis, and angioedema after eating sulfited foods in a restaurant. A single-blind challenge with no placebo
controls was conducted with sodium metabisulfite. Some of the symptoms (nausea, coughing, erythema of the patient’s skin) were reproduced by this challenge. Clayton and Busse
[26] reported a patient who developed anaphylaxis after ingesting wine. An open challenge with wine reproduced the patient’s symptoms of urticaria, angioedema, and hypotension. While this patient represents a possible case of sulfite sensitivity, specific testing
with sulfites was not conducted, nor was any association with sulfiting agents in wine recognized at that time.
Sokol and Hydick [27] identified a single case of sulfite-induced anaphylaxis presenting
with urticaria, angioedema, nasal congestion, and nasal polyp swelling that was later confirmed by multiple, single-blind, placebo-controlled oral challenge trials. The patient, who
had a history of similar food-related reactions, also produced a positive skin test to sulfite,
and histamine could be released from her basophils following incubation with sulfites.
Yang et al. [28] described three patients with systemic anaphylactic symptoms (rhinorrhea
with asthma in one, urticaria with asthma in the second, asthma only in the third) confirmed by sulfite challenge. These three patients had positive skin tests to sulfites, and two
of the three had positive Prausnitz-Küstner (PK) tests. One individual subsequently died,
allegedly after ingestion of sulfited food.
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Studies have been undertaken to determine whether sulfiting agent sensitivity frequently causes idiopathic anaphylaxis or chronic idiopathic urticaria [11, 29–31]. Sonin and
Patterson [29] conducted sodium metabisulfite challenges on 12 individuals with idiopathic
anaphylaxis, nine of whom reported episodes associated with restaurant meals. None of
the patients responded to the challenge. One additional patient with CIU and restaurantassociated symptoms was also challenged; this individual also failed to react to the challenge. Meggs et al. [11] studied 25 patients with idiopathic anaphylaxis. Two of the individuals reacted on single-blind challenge; after repeating the sulfite and placebo challenge,
one of these patients was subsequently found not to be sulfite sensitive. Another individual appeared to react on repeated challenge and not to placebo. However, institution of a
sulfite-free diet had no effect on this patient’s subsequent episodes. In a preliminary report
on 65 adults with CIU, none reacted to sulfites when appropriately challenged [30]. Using
a rigorous blinded, placebo-controlled trial and objective criteria for positive reactions,
Simon [31] was unable to demonstrate positive reaction to encapsulated metabisulfite (200 mg
maximum dose) in 75 patients with chronic urticaria and/or anaphylaxis with a history
suggestive of sulfite sensitivity.
Thus, although many adverse reactions have been ascribed to sulfiting agents, the risk
appears to be rather low for the nonasthmatic subject. Properly performed DBPC challenges are necessary to confirm whether sulfite sensitivity was responsible for suspected
adverse reactions.
Adverse reactions to sulfites from exposures via other routes
In addition, systemic adverse reactions have been attributed to intravenous, inhalation,
and other routes of administration of sulfiting agents contained in pharmaceutical products.
While receiving bronchodilator therapy with isoetharine, an asthmatic subject developed
acute respiratory failure that required mechanical ventilation [32]. The patient subsequently experienced erythematous flushing with urticaria upon IV administration of metaclopramide that contained a sulfiting agent. In placebo-controlled oral provocation with
sodium metabisulfite, this patient developed flushing without urticaria as well as a significant decrease in pulmonary function. Jamieson et al. [33] performed inhalation challenge
in a patient with presumed sulfite sensitivity. This individual experienced intense pruritis,
tingling of the mouth, nausea, chest tightness, and a feeling of impending doom. No placebo challenge was undertaken, however. Cutaneous exposure to sulfites can, on rare occasions, apparently elicit contact sensitivity reactions [14–16]. Schmidt et al. [34] posited
that sulfiting agents may have caused the appearance of a cardiac arrhythmia in a patient
given intravenous dexamethasone. This relationship was never confirmed by appropriate
challenge, however. Hallaby and Mattocks [35] attributed central nervous system toxicity
to the absorption of sodium bisulfite from peritoneal dialysis solutions. Wang et al. [36]
described eight patients who developed chronic neurological defects after receiving an
epidural anesthetic agent that contained sodium bisulfite as a preservative. Using an animal model, they demonstrated that the sulfiting agent produced a similar defect. Whether
the clinical manifestation in humans was directly attributable to the sodium bisulfite is
unknown.
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Asthmatic responses on exposure to sulfites through foods and drugs
Although sulfiting agents play a very limited and somewhat controversial role in the causation of nonasthmatic adverse reactions, their role in the causation of bronchospasm and
severe asthma is better established. Kochen [37] was among the first to suggest that ingestion of sulfited food can cause bronchospasm. He described a child with mild asthma who
repeatedly experienced coughing, shortness of breath, and wheezing when exposed to dehydrated fruits treated with sulfur dioxide that were packaged in hermetically sealed plastic bags. No direct challenge studies were conducted to confirm this observation, however.
Single-dose, open challenges without placebo control performed in a group of asthmatics
by Freedman [38, 39] suggested that sulfiting agents could trigger asthma. Eight of 14 subjects with a history of wheezing following consumption of sulfited orange drinks were
shown to experience changes in pulmonary function upon administration of an acidic solution containing 100 ppm (100 mg/l) of sodium metabisulfite.
The role of sulfite sensitivity in asthma became more widely recognized after reports
of Stevenson and Simon [5] and Baker et al. [4]. The initial studies of Stevenson and Simon
[5] demonstrated that placebo-controlled oral challenges with potassium metabisulfite
could produce significant changes in pulmonary function in certain asthmatics. Their first
subjects had severe, persistent asthma. In addition to their asthmatic response, these individuals experienced flushing, tingling, and faintness following sulfite challenges. Baker et
al. [4] showed that oral ingestion and intravenous administration of sulfites could cause
significant bronchoconstriction to the point of respiratory arrest in two individuals with
severe, persistent asthma.
Exposure to sulfiting agents may occur through ingestion and other routes. Sulfur dioxide generated from sulfited foods and drugs may be inhaled. Werth [40] described an
asthmatic individual who developed wheezing, flushing, and diaphoresis upon inhaling
the vapors released from a bag of dried apricots. The patient did not respond to ingested
metabisulfite in capsule form but reacted to inhalation of nebulized metabisulfite in distilled water. Reports have described several patients who suffered paradoxical responses
to the inhalation of bronchodilator solutions. Koepke et al. [41, 42] demonstrated that sodium bisulfite used as a preservative in bronchodilator solutions was capable of producing
bronchoconstriction. Other studies from this group [43] confirmed that the concentration
of metabisulfite contained in bronchodilator solutions could potentially generate 0.8–1.2
ppm of sulfur dioxide. Four of 10 subjects who tested negative to a capsule challenge with
metabisulfite reacted upon inhalation, whereas 10 nonasthmatic controls did not respond.
In addition to sulfiting agents administered intravenously, orally, or via inhalation, patients may respond to the topical application of sulfiting agents. Schwartz and Sher [44]
reported an individual who experienced a 25% decrease in FEV1 after application of one
drop of a 0.75 mg/ml potassium metabisulfite solution to the eye. This patient had previously experienced episodes of bronchoconstriction from the use of eye drops containing
sulfite preservatives for the treatment of glaucoma.
Asthmatic subjects may develop bronchoconstriction in response to a wide variety of
stimuli. Interestingly, a patient has been described [45] who failed to respond to typical
triggers of bronchoconstriction, including inhalation of methacholine and cold air hyperventilation, but who nevertheless experienced increased airway resistance and decreased

5

TAYLOR, BUSH, AND NORDLEE, FOOD ALLERGY (2014)

specific airway conductance following oral challenge with potassium metabisulfite. The
significance of this response remains unknown, as no changes in other parameters of pulmonary function, including FEV1, were observed.
The potential for fatal reactions from sulfite exposure has been confirmed [28, 46]. In
many instances, individuals who supposedly died from an adverse reactions to sulfite had
not undergone appropriate diagnostic challenges. Nonetheless, competent investigators
observed that severe bronchoconstriction, hypotension, and loss of consciousness can occur, demonstrating the potential for fatal reactions in some subjects—particularly those
with severe, persistent asthma.
Prevalence
Adult populations
The prevalence of adverse reactions to sulfiting agents is not precisely known. Although
attempts have been made to establish the prevalence of sulfite sensitivity in asthmatic subjects, the nature of the population studied and use of several different challenge methods
in these studies has resulted in some uncertainty regarding the prevalence estimates. Current estimates range from 3% to 10% of asthmatics [7]. Simon et al. [47] examined the prevalence of sensitivity to ingested metabisulfite in a group of 61 adult asthmatics. None
indicated a history of sulfite sensitivity. After challenges were conducted with potassium
metabisulfite capsules and solutions, a placebo-controlled challenge was used to confirm
positive responses. Five of 61 patients (8.2%) experienced a 25% or greater decline in FEV1
upon challenge.
Koepke and Selner [48] conducted open challenges with sodium metabisulfite in 15 adults
with a history of asthma after ingestion of sulfited foods and beverages. One of 15 patients
(7%) showed a 28% decline in FEV1; no confirmatory challenge was conducted. In a larger
study by Buckley et al. [49], 134 patients underwent single-blind challenges with potassium metabisulfite capsules. Of these subjects, 4.6% were suspected of having sulfite sensitivity. In these three studies, the population consisted of a large proportion of severe,
persistent asthma patients requiring oral steroids for therapy and who were being treated
at major referral centers, although sulfite sensitivity was diagnosed in several mild asthmatics as well [6]. Thus, the prevalence estimated from these studies may not be applicable
to the asthma population as a whole. Wuthrich [18] challenged 87 suspected, sulfite-sensitive
asthmatics (SSAs) with capsules containing sodium bisulfite (5–200 mg doses). Fifteen of
87 asthmatics (17.2%) reacted to these sulfite challenges, but the proportion of patients with
severe, persistent asthma in this study population was not determined. Because subjects
were selected for suspected sulfite sensitivity, the results of this study cannot be used to
assess the prevalence of sulfite sensitivity in the overall population of asthmatics.
In the largest study conducted to date, Bush et al. [7] conducted capsule and neutral
solution sulfite challenges in 203 adult asthmatics. None was selected based on a history
of sulfite sensitivity. Of these patients, 120 were not receiving oral corticosteroids, while 83
were. Of the patients not receiving oral steroids, only one experienced a 20% or greater
decline in FEV1 after single-blind and confirmatory double-blind challenge. The patients
receiving oral steroids had a higher response rate, estimated at approximately 8.4%. The
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prevalence in the asthmatic population as a whole was less than 3.9%, with patients with
severe, persistent asthma appearing to face the greatest risk.
Pediatric population
Limited studies have been conducted in children. Towns and Mellis [50] evaluated 29 children, aged 5.5–14 years, with moderate to severe asthma. Seven subjects had a history suggestive of sulfite sensitivity. Challenges were conducted with placebo on one day and with
sequential administration of sodium metabisulfite in capsule and solution form on a second day. Nineteen of 29 subjects showed a decrease in the peak expiratory flow rate varying from 23% to 72%, while peak expiratory flow rates with placebo were either unaffected
or dropped 19%. When a 20% decline in peak expiratory flow rate was viewed as a positive
response, 66% of these children were considered to be sulfite sensitive. Subsequently, the
patients were instructed to avoid sulfited food for 3 months. No overall significant improvement appeared in the patients’ asthma as a result of this avoidance diet.
Friedman and Easton [51] studied 51 children, aged 5–17 years. Eighteen of 51 (36%)
showed a 20% or greater decrease in FEV1 when provoked with potassium metabisulfite
in an acidic solution, although placebo challenges in these individuals showed only one
responder. The severity of asthma was not apparently correlated with the likelihood of a
positive sulfite challenge. Steinman et al. [52] evaluated 37 asthmatic children and determined that eight (22%) responded to double-blind challenges of sulfited apple juice with a
20% or greater decline in FEV1. An additional eight children were considered to experience
a reaction to sulfite when the criterion for a positive reaction was changed to a 10% or
greater decrease in FEV1. In contrast, a study by Boner et al. [53] determined that only four
of 56 asthmatic children (7%) responded to single-blind challenges with sulfite in capsules
and/or solutions. Furthermore, the sulfite-sensitive individuals displayed no additional
change in bronchial reactivity as assessed by methacholine challenges conducted after sulfite reactions. In this study, a positive response was defined as a 20% decline in FEV1.
Whether sulfite sensitivity really occurs more frequently in children has yet to be definitively established. Differences in challenge procedures (capsule vs. acidic beverage solutions) may account for the apparent observation of a higher prevalence in asthmatic
children. Nonetheless, the overall prevalence of sulfite sensitivity—particularly in adult
asthmatics—is small but significant. Severe, persistent asthmatics, particularly adult asthmatics, appear to be at greatest risk.
Mechanisms
The mechanisms of sulfite sensitivity remain unknown. Depending upon the route of exposure, a number of possible mechanisms have been hypothesized. Asthmatics are known
to respond with significant bronchoconstriction upon inhalation of less than 1 ppm of sulfur dioxide [54]. Fine and coworkers [55] demonstrated that bronchoconstriction developed in asthmatics who inhaled sulfur dioxide and bisulfite (HSO3−) but not sulfite (SO3=).
Alteration of airway pH itself did not cause bronchoconstriction. Thus, asthmatics may
respond differently to various ionic forms of sulfite that are dependent upon pH. Some
asthmatics also respond to either oral or inhalation challenge with sulfite, although
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inhalation appears more apt to produce a bronchoconstrictive response [56]. However, the
inhalation of sulfur dioxide or various sulfites may not be the total explanation. Field et al.
[57] challenged 15 individuals with increasing concentrations of SO2 gas or a metabisulfite
solution. All 15 subjects reacted to the metabisulfite solution, and 14 of the 15 reacted to
inhaled SO2 with a 20% or greater drop in FEV1. These investigators concluded that the
generation of SO2 gas cannot fully explain sulfite-induced asthma [57].
Considerable variability has been noted in the response to capsule and acidic beverage
challenges with sulfiting agents [58]. When challenged on repeated occasions, the same
group of individuals may not consistently experience bronchoconstriction. This variability
may provide some clues to understanding of the mechanism of sulfiteinduced asthma.
Inhalation during swallowing
In a study of 10 SSA subjects, Delohery et al. [59] demonstrated that all of the subjects
reacted to an acidic metabisulfite solution when it was administered as a mouthwash or
swallowed. However, none of these subjects reacted when the metabisulfite was instilled
through a nasogastric tube. These same individuals did not respond with changes in pulmonary function when they held their breath while swallowing the solution. A control
group of 10 non-SSAs showed no response to the mouthwash or swallowing challenge.
Delohery et al. [59] hypothesized that some individuals respond to these forms of challenge because they inhale sulfur dioxide during the swallowing process.
Linkage with airway hyperreactivity
Because asthmatics respond to various stimuli (airway irritants) at concentrations lower
than normal individuals (i.e., they exhibit airway hyperresponsiveness), attempts have
been made to link sulfite sensitivity with airway responsiveness to histamine and methacholine. Such an association has not been established [59, 60]. For example, Australian
investigators [57] were unable to demonstrate a relationship between the degree of airway
responsiveness to inhaled histamine and the presence of sulfite sensitivity.
In human studies, attempts to block the effect of metabisulfite by agents such as inhaled
lysine aspirin, inhaled indomethacin, and inhaled sodium salicylate demonstrated a slight
protective effect suggesting a possible role of prostaglandins in the mechanism of sulfite
sensitivity [61]. Further, leukotriene receptor antagonists attenuate SO2-induced bronchoconstriction, implying that leukotriene release may also be involved [62]. Administration
of the neutral endopeptidase inhibitor, thiorphan, was shown to enhance the airway response to inhaled sodium metabisulfite challenge in normal individuals [63]. This study
suggests that tachykinins may play a role in metabisulfite-induced bronchoconstriction [63].
This mechanism was also supported by observations in guinea pigs that capsaicin-sensitive
sensory nerves are involved in sulfite-induced bronchoconstriction [64]. Inhaled magnesium sulfate also has been shown to mildly inhibit inhaled metabisulfite-induced bronchoconstriction, but the mechanism is not known [65].
Refractoriness has been demonstrated to a number of indirect bronchoconstrictor stimuli including metabisulfite. The generation of nitric oxide as a possible explanation for the
refractoriness has been investigated in asthmatic subjects undergoing inhaled metabisulfite challenge [66]. Blockage of nitric oxide (NO) had no effect either on the response to
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metabisulfite per se or the refractory process suggesting that NO is not involved in metabisulfite-induced bronchoconstriction.
Other animal models demonstrated that application of sodium metabisulfite to trachea
of anesthetized sheep increased local blood flow and vascular permeability and induced
epithelial damage [67]. Sulfite-induced bronchoconstriction in sheep may also involve
stimulation of bradykinin B2 receptors which may subsequently activate cholinergic reflex
mechanisms [68].
Our group attempted to induce sulfite sensitivity in a group of 16 asthmatic subjects
(unpublished). After the provocative dose of methacholine producing a 20% decrease in
FEV1 was established, a sulfite challenge using an acidic sulfite solution was instigated to
identify any sulfite sensitivity. Three of the 16 subjects reacted to the sulfiting agent with
a 20% or greater decrease in FEV1. One week after this challenge, the patients underwent
bronchial challenge with an antigen to which they exhibited sensitivity. The following day,
the patients returned for a repeat methacholine challenge, followed by a second sulfite
challenge 24 hours later. After the antigen challenge, only one additional subject showed
a response to sulfiting agent that had not been present before antigen challenge. No significant increase was observed in airway response to methacholine. Thus, this study did not
link airway hyperreactivity and sulfite sensitivity. Similar negative results were obtained
in a study of asthmatic children [60].
Cholinergic reflux
Because sulfur dioxide may produce bronchoconstriction through cholinergic reflex mechanisms, preliminary studies have examined the effect of atropine and other anticholinergic
agents [69]. Inhalation of atropine blocked the airway response to sulfiting agents in three
of five subjects and partially inhibited the response in the other two subjects. Doxepin,
which possesses both anticholinergic and antihistaminic properties, had protective effects
in three of five individuals. In a study on sheep, inhaled metabisulfite induced bronchoconstriction that could be prevented by pretreatment with either ipratropium bromide or
nedocromil sodium but not by chlorpheniramine [68]. Sulfite-induced bronchoconstriction
in these sheep was also associated with a nine-fold increase in immunoreactive kinins.
Consequently, Mansour et al. [68] concluded that sulfite-induced bronchoconstriction in
sheep involves stimulation of bradykinin B2 receptors with subsequent activation of cholinergic mechanisms. Studies in guinea pigs suggest that capsaicin-sensitive sensory nerves
may play a role in sulfite-induced bronchoconstriction [64].
Possible IgE-mediated reactions
Adverse reactions to sulfites appear most commonly in atopic individuals, and studies
have attempted to identify an immunologic basis for these reactions. Several reports have
demonstrated positive skin tests to solutions of sulfiting agents in some sensitive patients.
The positive skin tests and other related evidence may point to the existence of an IgEmediated mechanism in at least some sulfite-sensitive individuals.
Prenner and Stevens [25] observed a positive scratch skin test to an aqueous solution of
sodium bisulfite at 10 mg/ml in a patient. This patient also exhibited a dramatic response
to intradermal testing at the same concentration. Three nonsensitive control subjects had
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negative skin tests. The patient of Twarog and Leung [32] also showed a positive intradermal skin test response to an aqueous solution of bisulfite at 0.1 mg/ml whereas controls were
negative with concentrations up to 1 mg/ml of the solution. Yang et al. [28] also identified
several asthmatic subjects with either positive prick or intradermal skin test to sulfites.
Boxer et al. [70] identified two additional cases with positive skin tests who also had positive oral challenges to sulfiting agents. Selner et al. [71] reported positive intradermal and
skin prick tests with 0.1 mg/ml and 10 mg/ml potassium metabisulfite solutions, respectively, in an SSA subject. This patient also had a positive intradermal test with a 0.1 mg/ml
solution of acetaldehyde hydroxysulfonate, a major bound form of sulfite in wine and other
foods [71]. Control subjects had negative skin tests.
Further evidence for an IgE mechanism can be found in positive passive transfer tests
(PK transfer). Several investigators have successfully transferred skin test reactivity to nonsensitized subjects with sera from sulfite-sensitive individuals [25, 28, 72]. The effect can
be abolished by heating sera to 56°C for 30 minutes [71]. These observations suggest the
presence of a serum factor (IgE). However, specific IgE antibodies to sulfiting agents have
not been demonstrated [70, 72].
In vitro activation of basophils by metabisulfites has been reported [73]. Sulfiting agents
can induce mediator release from human MCs and basophils obtained from some sensitive
individuals. Histamine release has been demonstrated in mixed peripheral blood leukocyte studies in sulfite-sensitive individuals [27, 32]. Similarly, Meggs et al. [11] noted a
significant rise in plasma histamine levels in two of seven subjects with systemic mastocytosis undergoing a sulfite challenge. No clinical response was observed in these patients,
however. In a skin-test-positive individual, sulfite exposure resulted in increased histamine levels in nasal lavage fluid 7.5 minutes after challenge [74]. Similar results were obtained in chronic rhinitis control subjects, although the histamine levels generally fell
below those found in patients with sulfite sensitivity [74]. In contrast, other investigators
have not been successful or noted inconsistent results in attempting to demonstrate histamine release from the MCs or basophils among sulfitesensitive individuals [5, 12, 74, 75].
Histamine, per se, may not play a significant role in sulfite-induced airflow obstruction
since H1 receptor antagonists fail to block the response [62].
Indirect evidence for the role of MC mediators in the production of bronchoconstriction
due to sulfiting agents has also been found. Freedman [39] mentions that inhaled sodium
cromolyn prevented the asthmatic response. In preliminary studies, Simon et al. [69] found
that inhaled cromolyn inhibited sulfite-induced asthma in four of six subjects and partially
inhibited the response in two other subjects. Schwartz [76] reported that oral cromolyn at
a dose of 200 mg blocked an asthmatic response to oral sulfite challenge in a single individual.
Sulfite oxidase deficiency
Simon [75] proposed that a deficiency in sulfite oxidase, an enzyme that metabolizes sulfite
to sulfate, may promote sulfite-induced adverse reactions. The skin fibroblasts of six sulfitesensitive subjects exhibited less sulfite oxidase activity than normal controls. However, the
major source of sulfite oxidase activity in humans resides in the liver. In addition,
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congenital sulfite oxidase deficiency in humans is not associated with asthma [77]. Further
investigation will be needed to determine the importance of this suggested mechanism.
Diagnosis
The diagnosis of sulfite sensitivity cannot be established by the patient’s history alone. Our
group [7] was unable to correlate the presence of a positive sulfite challenge with the patient’s history, and vice versa. The diagnosis of sulfite sensitivity should, therefore, be made
only in individuals who demonstrate an objective response upon appropriate challenge.
Skin testing—by both prick and scratch methods—has identified some individuals with
positive responses [28, 70]. Basophil activation tests may eventually prove useful [73]. In
contrast, some individuals who have equally severe bronchospasm or other reactions had
negative skin tests.
Diagnostic challenges
Because diagnostic challenges represent the only effective confirmatory technique, and because such challenges may pose significant risk to sensitive subjects, patients must be informed of the risks involved. Physicians instituting such provocation procedures should
have available all equipment necessary for the treatment of severe bronchospasm or anaphylaxis, including airway intubation and mechanical ventilation. The end point for objective assessment of reactivity should be ascertained before the challenge begins. Such
measures might include changes in airway function in asthmatics or the appearance of
urticaria in patients with this type of response. Patients may be challenged with capsules,
neutral solutions, or acidic solutions of metabisulfite. Some protocols previously reported
in the literature are shown in Tables 1 and 2 [78]. Currently, a capsule challenge is the
preferred option, as most sulfite exposure is likely to involve bound forms of sulfites in
foods rather than solutions.
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Table 1. Capsule and neutral-solution metabisulfite challengea
Preparing the patient and collecting preliminary data
• Withhold short-acting aerosol sympathomimetics and cromolyn/nedocromil sodium for 8 h and shortacting antihistamines for 24–48 h before pulmonary function testing.
• Measure pulmonary function: forced expiratory volume in 1 s (FEV1) must be greater than or equal to 70%
of predicted normal value and greater than or equal to 1.5 l in adults. (Test contraindicated in patients with
an FEV1 below those levels. Standards for children have not been defined).
Performing the single-blind challenge
• Administer placebo (powdered sucrose) in capsule form. Measure FEV1.
• Administer capsules containing 1, 5, 25, 50, 100, and 200 mg of potassium metabisulfite at 30-min intervals.
Measure FEV1 30 minutes after administering each dose and if the patient becomes symptomatic.
• If no response, administer 1, 10, and 25 mg of potassium metabisulfite in water-sucrose solution at 30-min
intervals. Measure FEV1 30 min after each dose and if symptoms occur. Positive response is indicated by a
decrease in FEV1 of 20% or more.
Performing the double-blind challenge
• Perform challenge and placebo procedures on separate days, in random order.
• Placebo day: administer only sucrose in capsules and solution. Measure FEV1 30 min after each dose and
if patient becomes symptomatic.
• Challenge day: same protocol as single-blind challenge day.
Source: From Reference 78.
aProtocol used in the University of Wisconsin prevalence study [7]. Perform this test only where the capability
for managing severe asthmatic reactions exists. Stop challenge sequence after a positive response is obtained.

Table 2. Acid-solution metabisulfite challengea
Preparing the patient and collecting preliminary data
• Withhold aerosol sympathomimetics and cromolyn sodium for 8 h and antihistamines for 24–48 h before
pulmonary function testing.
• Measure pulmonary function: forced expiratory volume in 1 s (FEV1) must be greater than or equal to 70%
of predicted normal value and greater than or equal to 1.5 l in adults. (Test contraindicated in patients with
an FEV1 below those levels. Standards for children have not been defined).
Performing the bisulfite challenge
• Dissolve 0.1 mg of potassium metabisulfite in 20 ml of a sulfite-free lemonade crystal solution. Have the
patient swish the solution around for 10–15 s, then swallow.
• Measure FEV1 10 minutes after the first dose. Then, administer 0.5, 1, 5, 10, 15, 25, 50, 75, 100, 150b, and
200b mg per 20 ml of the solution at 10-min intervals. Measure FEV1 10 min after each incremental increase
in dose. Positive response is signified by a decrease in FEV1 of 20% or more.
Source: From Reference 78.
aProtocol investigated by the Bronchoprovocation Committee-American Academy of Allergy, Asthma and
Immunology. Perform this test only where the capability for managing severe asthmatic reactions exists. Stop
challenge sequence after a positive response [78].
bDoses in excess of 100 mg are likely to produce nonspecific bronchial reactions in asthmatics due to the high
levels of free SO2 that are generated.
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When conducting challenges in a single-blind fashion, positive results should be confirmed via a double-blind procedure. Moreover, if a placebo day and an active challenge
day are conducted on two separate occasions, the possibility of order effects on the results
must be considered. For example, if a patient receives placebo on the first day and experiences no response, he or she may experience a reaction on the subsequent challenge day
regardless of whether placebo or active challenge with sulfite is administered because of
increased anxiety. To overcome this possibility, the order of administration of active and
placebo challenges should be randomized and a third challenge day, either active or placebo, potentially instituted.
Treatment
Avoidance of sulfited foods and drugs
Sulfite-sensitive individuals should avoid sulfite-treated foods [79, 80] and drugs [78, 81]
that have been shown to trigger the response. Because individuals may vary in their sensitivity to sulfited foods, it may be necessary to perform challenges with foods containing
sulfites to determine which ones the patient can tolerate.
Some bronchodilator solutions, subcutaneous lidocaine, intravenous corticosteroids,
and intravenous metaclopramide may pose a risk for sensitive subjects. Many pharmaceutical companies are aware of this possibility, however, and are taking steps to eliminate
sulfiting agents from their products. A partial list of sulfited medications appears in Table
3. Package inserts for suspect medications should be consulted for the latest information.
Table 3. Some antiasthma preparations containing sulfites
Epinephrine

Adrenalin, Monarch
TwinJectTM, versus Pharmaceuticals Epi-PenTM, Dey Laboratories
Multiple manufacturers

Isoproterenol solutions

IsuprelTM, Sanofi-Winthrop
Isoproterenol, Elkins-Sinn

Injectable corticosteroid

DecadronTM, Merck Dexamethasone, multiple manufacturers

Use of injectable epinephrine
Although some forms of epinephrine contain sulfite used as a preservative, administration
of this drug has not been shown to cause a reaction in sulfite-sensitive individuals. Apparently, epinephrine’s action overcomes any adverse effects attributable to the preservative.
Thus, patients who are inadvertently exposed to sulfites typically find self-administration
of epinephrine useful. Self-injection with an automatic dispenser of epinephrine, delivering 0.3 ml of a 1:1000 solution (0.3 mg) for adults, is available (Epi-Pen, Dey Inc., Napa,
California). A similar device available for children delivers 0.15 ml of a 1:1000 solution of
epinephrine.
Use of blocking agents
Limited studies have been conducted with a variety of agents that may block the responses
to sulfite, including cromolyn sodium, atropine, doxepin, vitamin B12, inhaled furosemide
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and leukotriene receptor antagonists [8, 69, 82]. Although these treatments have demonstrated beneficial effects in limited numbers of patients, they remain investigational and
cannot be recommended for standard use.
A better understanding of the mechanisms involved in sulfite sensitivity would allow
for more specific interventions to treat and perhaps prevent these reactions.
Food and drug uses
Sulfiting agents are added to many different types of foods for several distinct technical
purposes (Table 4). The key technical attributes of sulfites in foods include the inhibition
of enzymatic and nonenzymatic browning, antimicrobial actions, dough-conditioning effects, antioxidant purposes, bleaching applications, and a host of other uses characterized
as processing aids [1]. Some uses of sulfites, such as their application to fresh fruits and
vegetables (except potatoes) to inhibit enzymatic browning, have now been restricted by
federal regulatory actions in the United States, as will be described later in this chapter.
Because of their important technical attributes, sulfites are utilized in an enormous number
of specific applications in a wide variety of foods, as reviewed elsewhere [1, 83].
Table 4. Technical attributes of sulfites in foods
Technical Attribute

Examples of Specific Food Applications

Inhibition of enzymatic browning

Fresh fruits and vegetablesa
Saladsa
Guacamolea
Shrimp (black spot formation)
Pre-peeled raw potatoes

Inhibition of nonenzymatic browning

Dehydrated potatoes
Other dehydrated vegetables
Dried fruits

Antimicrobial actions

Wines
Corn wet milling to make cornstarch, corn syrup

Dough conditioning

Frozen pie crust
Frozen pizza crust

Antioxidant action

No major U.S. applications

Bleaching effect

Maraschino cherries
Hominy

aNo

longer allowed by the U.S. Food and Drug Administration

Given the wide variety of applications for sulfites in foods, a broad range of use levels
and residual sulfite concentrations can be found in foods (Table 5). Residual sulfite concentrations in foods can range from undetectable (less than 10 ppm) to more than 2000
ppm (mg SO2 equivalents per kg of food). Although SSAs vary in their degree of sensitivity
to ingested sulfites, all such individuals can tolerate some sulfite. Certainly, the more
highly sulfited foods pose the greatest hazard to SSAs.
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Table 5. Estimated total SO2 level as consumed for some sulfited foods
> 100 ppm
Dried fruit (excluding dark raisins and prunes)
Lemon juice (nonfrozen)
Lime juice (nonfrozen)
Wine

Molasses
Sauerkraut juice
Pickled cocktail onions
Grape juice (white, white sparkling, pink sparkling,
red sparkling)

50–99.9 ppm
Dried potatoes
Wine vinegar
Gravies, sauces

Fruit topping
Maraschino cherries

10.1–49.9 ppm
Pectin
Shrimp (fresh)
Corn syrup
Sauerkraut
Pickled peppers
Pickles/relishes

Corn starch
Hominy
Frozen potatoes
Maple syrup
Imported jams and jellies
Fresh mushrooms

< 10 ppm
Malt vinegar
Dried cod
Canned potatoes
Beer
Dry soup mix
Soft drinks
Instant tea
Pizza dough (frozen)
Pie dough

Sugar (esp. beet sugar)
Gelatin
Coconut
Fresh fruit salad
Domestic jams and jellies
Crackers
Cookies
Grapes
High fructose corn syrup

Source: Adapted from The Reexamination of the GRAS Status of Sulfiting Agents. Life Science Research Office,
Federation of American Societies for Experimental Biology, January 1985.

Sulfites are added to many pharmaceutical products [2, 3]. Table 3 contains a list of
drugs intended for asthmatics that may contain sulfites. With the increased concern over
sulfite-induced asthma, these substances have been removed from some drugs in recent
years, especially from drugs intended for asthmatics. Sulfites are used in drugs intended
for oral, topical, respiratory, and internal use.
Sulfites have two primary functions as drug ingredients: to prevent the oxidation of
active drug ingredients and to prevent nonenzymatic browning, which involves the reactions of reducing sugars with amino acids or amines that can occur in enteral feeding solutions and dextrose solutions. The latter stages of the nonenzymatic browning reaction
involve the condensation of quinones. Epinephrine can undergo a similar reaction that diminishes its potency. Consequently, sulfites are routinely added to epinephrine to prevent
such condensation reactions.
The usage levels of sulfites in pharmaceutical products vary from 0.1% to 1%, although
a few products may contain higher concentrations. Exposure to sulfites via drugs can be
high but would be sporadic in most cases. The active ingredients of the drug may, in a few
cases, counteract the effects of sulfite in sulfite-sensitive individuals. Until recently, sulfites
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were common additives in certain bronchodilators but, except in a few rare cases [41], the
bronchodilating effect of the active ingredient overwhelms the bronchoconstricting effect
of sulfite. As noted earlier, epinephrine easily overwhelms the bronchoconstricting effects
of sulfites. Thus, sulfite-containing epinephrine should never be denied to or avoided by
an SSA because it can act as a life-saving antidote [2, 84].
Fate of sulfites in foods
SO2 and its sulfite salts are extremely reactive in food systems. The wide range of technical
attributes of sulfites in foods is a direct result of this reactivity. Thus, these substances often
react with a variety of food components. A dynamic equilibrium exists between free sulfites and the many bound forms of sulfite [1]. Thus, the fate of these food additives will
vary widely, depending on the nature of each individual food.
SO2 and the sulfite salts readily dissolve in water and, depending upon the pH of the
medium, can exist as sulfurous acid (H2SO3), bisulfite ion (HSO3−), or sulfite ion (SO3=) [81].
All of these forms react with a variety of food components with the extent and reversibility
of these reactions relating to pH. At acidic pHs (pH of less than 4), SO2 can be released as
a gas from a sulfite-containing food or solution. Thus, sulfites can actually be lost from
foods, albeit only under acidic conditions.
Sulfites react readily with food constituents including aldehydes, ketones, reducing
sugars, proteins, amino acids, vitamins, nucleic acids, fatty acids, and pigments, to name
but a few [1]. The extent of any reaction between sulfite and some food component is dependent on the pH, temperature, sulfite concentration, and reactive components present
in the food matrix. An equilibrium always exists between free and bound sulfites, although
the reversibility of the reactions varies over a wide range [1, 83]. Some reactions, such as
the one between acetaldehyde and sulfite to form acetaldehyde hydroxysulfonate, are virtually irreversible. Other reactions, such as between the anthocyanin pigments of fruits
and sulfite, reverse readily. The binding of sulfite by various food constituents diminishes
the concentration of free sulfite in the food. While the dissociable, bound forms of sulfite
can serve as reservoirs of free sulfite in the food, irreversible reactions tend to remove sulfite permanently from the pool of free sulfite. The desirable actions of sulfites in foods frequently depend on free sulfite, so the concentration of the pool of free sulfite represents a
critically important factor in technical effectiveness. Therefore, treatment levels for specific
food applications aim to provide an active, residual level of free sulfite throughout the
shelf life of the product.
In lettuce, high concentrations of sulfite (500–1000 ppm) were once used to prevent enzymatic browning. Because lettuce consists mostly of cellulose and water, the sulfite had
few components with which to react. Consequently, most of the sulfite added to lettuce
lingered in the form of free inorganic sulfite [85]. Lettuce is unique in this regard, as most
foods contain substances that readily react with sulfites. In most foods, therefore, the
bound forms of sulfite would predominate.
A comprehensive discussion of the possible reactions between sulfites and food constituents lies beyond the scope of this chapter. An entire book has been written on the subject of the chemistry of sulfites in foods [83]. Suffice it to say that the fate of sulfites in
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individual food products is dynamic, extraordinarily complex, and difficult to predict with
any degree of precision.
Likelihood of reactions to sulfited foods
Few trials have attempted to evaluate the sensitivity of SSAs to sulfited foods. Based on
the suspected mechanisms of sulfite-induced asthma, one might predict that acidic foods
and beverages capable of generating SO2 gas would be more hazardous than other forms
of sulfited foods. Clinical challenges with acidic solutions of sulfite in lemon juice or some
other vehicle appear to support this conclusion [59, 84]. In all foods, the fate of sulfite may
be an important determinant of the degree of hazard faced by the sulfite-sensitive consumer. Little evidence currently exists, however, regarding the hazard levels posed by the
various forms of food-borne sulfite. The overall concentration of residual sulfite in the food
also represents an important determinant of the likelihood of a reaction.
Clinical challenges have documented several features of sulfite-induced asthma. First,
all SSAs exhibit some tolerance for ingested sulfite. The threshold levels vary from one
patient to another, ranging from approximately 0.6 mg of SO2 equivalents (1 mg of K2S2O5)
to levels greater than 120 mg of SO2 equivalents (200 mg of K2S2O5). Second, clinical challenges have confirmed that free, inorganic sulfite presents a hazard to SSAs. Third, more
asthmatics will respond to inhalation of SO2 or ingestion of acidic sulfite solutions than to
ingestion of sulfite in capsules.
From these facts, several predictions can be made about the likelihood of reactions to
sulfited foods among SSAs. First, reactions will be more likely and probably more severe
to highly sulfited foods such as lettuce, dried fruit, and wines. Certainly, no evidence exists
to implicate foods with low levels of residual sulfite (from less than 10 ppm to 50 ppm) in
adverse reactions in sensitive individuals [86, 87]. Second, foods containing a higher proportion of free inorganic sulfite may offer greater risks than foods in which the bound
forms of sulfite predominate. Sulfited lettuce is certainly the best example of a food with a
high proportion of free inorganic sulfite [85]. This prediction assumes, however, that the
bound forms of sulfite are less hazardous than free inorganic sulfite—an assumption that
has not been clinically established. Finally, one might predict that acidic foods or beverages
containing sulfites would pose greater danger than other sulfited foods. Examples of these
hazardous foods would include wines, white grape juice, nonfrozen lemon and lime juices,
and perhaps lettuce treated with an acidic salad freshener solution. These predictions appear to match the practical experiences of SSAs.
Few experiments have been conducted to test these predictions. Halpern et al. [87]
tested 25 nonselected asthmatics with 4 oz of white wine containing 160 mg of SO2 equivalents per liter. Because patients were not prescreened for sulfite sensitivity, the results of
this clinical trial are difficult to evaluate. Only one (4%) of the 25 patients exhibited reproducible symptoms with the wine challenge, however.
Howland and Simon [88] conclusively demonstrated that sulfited lettuce can trigger
asthmatic reactions in confirmed SSAs. The five patients in this trial were exposed to 3 oz
of lettuce containing 500 ppm of SO2 equivalents. All of these patients had documented
reactions to sulfite ingested in capsule form. Taylor et al. [79] confirmed the reactivity of
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SSAs to ingestion of sulfited lettuce, including one subject who responded to only acidic
solution challenges of sulfite.
In their study, Taylor et al. [79] assessed the sensitivity of eight SSAs to a variety of
sulfited foods, including lettuce, shrimp, dried apricots, white grape juice, dehydrated potatoes, and mushrooms. Sulfite sensitivity was confirmed by double-blind, capsule-beverage
challenges. Despite the positive double-blind challenges, four of these patients failed to
respond to any of the sulfited foods or beverages. The other four patients experienced
bronchoconstriction after ingesting sulfited lettuce, although this test was the only positive
food challenge for the acidic beverage reactor. Curiously, this patient did not react adversely to a challenge with white grape juice, which is an acidic, sulfited beverage. Two of
the remaining three patients also reacted to dried apricots and white grape juice; the third
patient did not complete these challenges. Only one of the three patients reacted to challenges with dehydrated potatoes and mushrooms; in the case of dehydrated potatoes,
however, her response to multiple double-blind challenges with dehydrated potatoes was
not consistent. None of these patients responded to sulfited shrimp.
While these results were somewhat confusing, they illustrated that SSAs will not react
equivalently to the ingestion of all sulfited foods. The likelihood of a response could not
be predicted on the basis of the dose of residual SO2 equivalents in the sulfited foods. The
nature of the sulfite present in these foods varied widely. In lettuce, the sulfite level is high
and free inorganic sulfite predominates [85]. In white grape juice and especially dried apricots, the sulfite level is high, the foods are acidic, and sulfite may be bound to reducing
sugars [1, 79]. In dehydrated potatoes, the sulfite level is intermediate, the food is not
acidic, and sulfite is typically bound to starch [1, 79]. In mushrooms, the sulfite level is low
and variable, but the form of sulfite remains unknown. In shrimp, the sulfite level is intermediate, the food is not acidic, and sulfite is probably bound to protein [1, 79]. The likelihood of a reaction to a sulfited food depends on several factors: the nature of the food, the
level of residual sulfite, the sensitivity of the patient, and (perhaps) the form of residual
sulfite and the mechanism of sulfite-induced asthma [79].
Avoidance diets
As noted earlier, the most common treatment for individuals with sulfite-induced asthma
is the avoidance of sulfite in the diet. Of course, asthmatics with a low threshold for sulfites
must take greater care to avoid these substances than individuals with higher thresholds.
Certainly, all SSAs should be instructed to avoid the more highly sulfited foods, which are
defined as having in excess of 100 ppm of SO2 equivalents (Table 5). Individuals with
lower thresholds for sulfite might be advised to remove all sulfited foods from their diets,
although adherence to such diets can prove difficult. Packaged foods containing more than
10 ppm residual SO2 equivalents must declare the presence of sulfites or one of the specific
sulfiting agents on their labels. Thus, sulfite-sensitive consumers should be able to avoid
significantly sulfited foods by careful perusal of labels. They must also be instructed that
the terms sulfur dioxide, sodium or potassium bisulfite, sodium or potassium metabisulfite, and sodium sulfite indicate the presence of sulfites or sulfiting agents. Some sulfitesensitive individuals may know that they can safely consume certain foods declaring
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sulfite on the labels because the amount of available sulfite in that particular food falls
below their threshold doses. Such patients should be warned that the concentration of residual sulfite in any specific food is variable and that continued consumption might occasionally elicit an adverse reaction. No absolute evidence exists to suggest that sulfitesensitive individuals need to avoid foods having less than 10 ppm residual SO2 equivalents.
While the avoidance of sulfited packaged foods is relatively straightforward, restaurant
foods pose a more difficult challenge. The FDA has banned sulfite from fresh fruits and
vegetables in restaurants, but other sulfited foods in restaurants remain unlabeled. With
the banning of sulfites from salad bar items, many of the problems with sulfite-induced
asthma in restaurants have disappeared. The major continuing problem is sulfited potatoes. SSAs should be instructed to avoid all potatoes products in restaurants except baked
potatoes with the skins intact.
US regulatory agencies have moved to regulate certain uses of sulfites following the
discovery of sulfite-sensitive asthma. The FDA initially moved to require the declaration
of sulfites on the label of foods when sulfite residues exceeded 10 ppm; similar regulations
were enacted with wines. The FDA then banned the use of sulfites from fresh fruits and
vegetables other than potatoes. This ban affected lettuce, cut fruits, guacamole, mushrooms, and many other applications, especially the once-common practice of sulfiting fresh
fruits and vegetables placed in salad bars. Potatoes remain the sole exception to the ban of
sulfite use on fresh fruits and vegetables. Since the FDA has taken these regulatory actions
on sulfites, the number of sulfite-induced reactions reported to the FDA has decreased.
While FDA actions have helped to protect sulfite-sensitive individuals from the hazards
associated with sulfited foods, FDA has taken no action to limit the use of sulfites in drugs.
However, voluntary removal of sulfites from certain drugs has occurred in some instances.
Certainly, any regulation is only as effective as its enforcement, so sulfite-sensitive individuals and their physicians should remain alert to avoid inadvertent exposures from both
foods and drugs.
Conclusion
Sulfite sensitivity primarily affects a relatively small subgroup of the asthmatic population.
The symptoms of sulfite-induced asthma can, on occasion, prove quite severe and even
life-threatening. Sulfite sensitivity should ideally be diagnosed with an oral double-blind
challenge protocol. Many unknowns remain regarding sulfite-induced asthma, including
the mechanism of the illness and the likelihood of reactions to specific sulfited foods. Reactions to sulfited foods certainly derive in part from the concentration of residual sulfite
in the food and the degree of sensitivity exhibited by the individual patient. In addition,
the form of sulfite in the food and the mechanism of the sulfite-induced reaction may affect
the likelihood of a response to a specific sulfited food.
SSAs should be instructed to avoid highly sulfited foods. The FDA and other US federal
regulatory agencies have moved to protect SSAs from unlabeled uses of sulfites in foods.
Nevertheless, sulfites continue to be used in many foods and drugs, and sensitive individuals must be cautious to avoid inadvertent exposures.
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